Recent Updates
Recently added Catalysts

LY3839056

Phase 1

Undisclosed | Small Molecules | Other |Eli Lilly and Company|Trials Updated: Nov 20, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment64

FDA Designations

No designations recorded

LY3839056 clinical trials

LY3839056 · 1 trial · 1 indication

Phase 1 1
NCT07945314A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy ParticipantsHealthy Participants
NOT YET_RECRUITING64 Analytics
PHASE1NOT YET_RECRUITING
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
Healthy ParticipantsUnlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.
Baseline through Day 85

Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs.

Secondary Endpoints

PK: Cmax
Predose on Day 1 up to Day 85
PK: AUC
Predose on Day 1 up to Day 85
PK: t1/2
Predose on Day 1 up to Day 85
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Cohort 1 IVEXPERIMENTALParticipants will receive LY3839056 Intravenously
Cohort 2 IVEXPERIMENTALParticipants will receive LY3839056 Intravenously
Cohort 3 IVEXPERIMENTALParticipants will receive LY3839056 Intravenously
Cohort 4a IVEXPERIMENTALParticipants will receive LY3839056 Intravenously
Cohort 4b SCEXPERIMENTALParticipants will receive LY3839056 Subcutaneously
Cohort 5 IVEXPERIMENTALParticipants will receive LY3839056 Intravenously
Cohort 6a IVEXPERIMENTALParticipants will receive LY3839056 Intravenously
Cohort 6b SCEXPERIMENTALParticipants will receive LY3839056 Subcutaneously
Placebo IVPLACEBO_COMPARATORParticipants will receive Placebo Intravenously
Placebo SCPLACEBO_COMPARATORParticipants will receive Placebo Subcutaneously

Interventions

NameTypeDescription
LY3839056 IVDRUGLY3839056 Administered Intravenously
Placebo IVDRUGPlacebo Administered Intravenously
LY3839056 SCDRUGLY3839056 Administered Subcutaneously
Placebo SCDRUGPlacebo Administered Subcutaneously
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Key Inclusion Criteria: * Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring. * Have clinical laboratory test results within normal reference range for the population or the clinical research site, or re...

Countries:China
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 20, 2026NCT07945314lastUpdatePostDate: changed
LOWNov 18, 2026NCT07945314NEW_TRIAL: changed
LOWNov 18, 2026NCT07945314NEW_TRIAL: changed